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Abstract 
Background: Although coronary artery disease and arterial hypertension are the most common 
etiologies underlying heart failure (HF), there are still many patients present with non-ischemic and 
non-hypertensive HF whose management remains very challenging. In this research study the clinical 
profile and applied treatment of patients with HF without coronary artery disease or hypertension versus 
patients with known etiology of HF (ischemic/hypertensive) were compared.
Methods: Clinical data about 5563 patients with stable systolic HF were obtained from prospective 
multicenter DATA-HELP registry performed between October and December 2009 in ambulatory clinics 
in Poland, in which 500 cardiologists and 290 general practitioners participated. 
Results: Heart failure of non-ischemic and non-hypertensive etiology which affected 10% of all patients 
and was particularly frequent in younger patients, both in women: < 50 years old 42%; 50–65 years 
old 12%; > 65 years old 7%; and men: < 50 years old 47%; 50–65 years old 10%; > 65 years old 5%;  
p < 0.0001. Patients with non-ischemic and non-hypertensive HF were characterized by younger age, 
fewer co-morbidities, shorter duration of HF and, surprisingly, more advanced HF. Patients in this 
group were less likely to have received life-prolonging treatment in HF recommended by European 
Society of Cardiology (ESC) and more often required symptomatic management. Similarly, they were 
more likely to have implanted CRT-D and ICD.
Conclusions: Heart failure of non-ischemic and non-hypertensive origin affects particularly young 
patients. These patients, despite suffering from more advanced HF are not optimally managed according 
to ESC guidelines. (Cardiol J 2018; 25, 4: 512–520)
Key words: DATA-HELP registry, heart failure with reduced ejection fraction,  
non-ischemic heart failure, Poland, systolic heart failure
Introduction
Heart failure (HF) is a clinical syndrome with 
many different underlying etiologies such as coro-
nary artery disease, hypertension, myocarditis, 
valvular heart disease, arrhythmias, alcoholism, 
lysosomal storage diseases or amyloidosis [1–5].
Despite the fact that there have been substan-
tial improvements in the management of HF in 
recent years, HF continues to encounter problems 
CLINICAL CARDIOLOGY
Cardiology Journal 
2018, Vol. 25, No. 4, 512–520
DOI: 10.5603/CJ.a2017.0046 
Copyright © 2018 Via Medica
ISSN 1897–5593
512 www.cardiologyjournal.org
ORIGINAL ARTICLE
with high mortality, morbidity and an increasing 
rate of recurrent hospitalizations due to decom-
pensated chronic HF [1, 6–9]. Therefore, currently 
a key issue is to optimize outpatient treatment of 
HF. The role of ambulatory treatment and follow-up 
provided by general practitioners and outpatient 
cardiac clinics cannot be underestimated in an 
effective rapid response to first signs of decom-
pensation and in optimization of pharmacotherapy 
to slow down HF progression.
Thanks to clinical trials including patients 
with ischemic and hypertensive etiology of HF, we 
have implemented European Society of Cardiology 
(ESC) guidelines helpful in managing patients with 
HF according to the evidence based medicine. 
However, in contrary to well-established treatment 
of patients with ischemic and hypertensive origin 
of HF, there is a lack of clinical trials on other HF 
etiologies, and accordingly their management ap-
pears to be less clear [1].
The aim of this study was to investigate the 
Polish population of outpatients with systolic HF 
and to compare the clinical profile and applied 
treatment in patients with non-ischemic, non-
hypertensive HF versus patients with ischemic 
or hypertensive etiology of HF.
Methods
Study population and protocol
A prospective multicenter DATA-HELP (Di-
Agnotic and TherApeutic methods used in patients 
with systolic HEart Failure Living in Poland) study 
was performed between October and December 
2009 in Poland. Stratified randomization was con-
ducted by Cegedim Strategic Data among all gen-
eral practitioners (GPs) and cardiologists working 
in outpatient clinics with the algorithm based on the 
generation of pseudorandom numbers according to 
Wichman and Hill [10]. A random sample of physi-
cians (500 cardiologists and 290 GPs) were invited 
to complete a questionnaire regarding the clinical 
status, medical history, administered diagnostic 
tests, applied therapy, recent hospitalizations and 
outpatient visits in 10 consecutive patients with 
systolic HF. Physicians were instructed to recruit 
patients with stable systolic HF and made responsi-
ble for the complex management of their treatment. 
Recruited patients had to fulfil the following 
inclusion criteria: 
 — age ≥ 18 years; 
 — clinical diagnosis of HF based on current Eu-
ropean recommendations; 
 — left ventricular ejection fraction (LVEF) ≤ 45%;
 — outpatient visit from October to December 
2009.
This investigation conformed with the princi-
ples outlined in the Declaration of Helsinki. The 
study protocol was registered and approved by all 
involved ethics committees.
Detailed clinical data about information obtained 
from the questionnaires were completed by cardiolo-
gists and general practitioners about their outpatients 
with stable systolic HF are contained in the paper 
‘Comparison of clinical profile and management of 
outpatients with HF with reduced LVEF treated by 
general practitioners and cardiologist in contemporary 
Poland: the results from the DATA-HELP registry’ 
Jankowska et al. (paragraph 2.2. Information obtained) 
[11]. Additionally, information about the number and 
kind of hospitalizations (urgent vs. planned; in cardiac 
vs. in other departments) and outpatient visits (in 
internal medicine vs. cardiac clinics vs. general practi-
tioner practice vs. other specialized outpatient clinics) 
within 12 months preceding the study was obtained.
Studied groups
All outpatients with stable systolic HF re-
cruited into the DATA-HELP registry were divided 
into three groups according to the etiology of HF:
 — patients with non-ischemic, non-hypertensive 
etiology (study group, in which the background 
of hypertensive and ischemic heart disease 
was excluded by their GP/cardiologist);
 — patients with ischemic etiology (with coronary 
artery disease as a major underlying etiology 
of HF, with previous myocardial infarction 
and/ or after revascularization — percutane-
ous coronary intervention [PCI] or coronary 
artery bypass grafting [CABG]);
 — patients with arterial hypertension without 
concomitant coronary artery disease.
Statistical analyses
Continuous variables were expressed as mean 
± standard deviations when they were normally 
distributed or medians with lower and upper quar-
tiles for variables with a skewed distribution. The 
categorized variables were presented as numbers 
with percentages. The statistical significance of 
differences between the groups were tested us-
ing analysis of variance (Kruskal-Wallice test), 
Student’s t-test, or the c2 test, where appropriate.
A value of p < 0.05 was considered statisti-
cally significant.
Statistical analyses were performed using 
STATISTICA 10 data analysis software system 
(StatSoft, Inc).
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Results
5563 outpatients with systolic HF were en-
rolled in the study — 59% data (3300 patients) 
came from outpatient cardiology practices and 34% 
(1895 patients) from GPs. 10% (546) of patients had 
etiologies other than ischemic and hypertensive, 
whereas in 76% of patients coronary artery disease 
was the leading cause of HF (Fig. 1). Both in men 
and women, the prevalence of non-ischemic and 
non-hypertensive HF decreased with the increas-
ing age. Among younger patients (< 50 years old) 
every second patient with systolic HF had neither 
hypertensive nor ischemic heart disease (Figs. 2, 3).
In the non-ischemic and non-hypertensive 
groups there were patients with a shorter duration 
of the disease than in the ischemic group (Table 1). 
Patients in non-ischemic and non-hypertensive 
group were characterized by younger age and fewer 
co-morbidities (diabetes mellitus type 2, previous 
stroke/transient ischemic attack, chronic obstruc-
tive pulmonary disease/asthma). In this group pa-
tients experienced more advanced HF, here defined 
as more severe symptoms of HF classified as New 
York Heart Association (NYHA) class III or IV, 
on physical examination (pulmonary congestion, 
hepatomegaly, jugular vein distension, third heart 
sounds) and LVEF < 20% (Table 1).
Patients with non-ischemic and non-hyper-
tensive HF received beta- blockers less frequently 
and angiotensin converting enzyme inhibitor/ 
/angiotensin receptor blocker (ACEI/ARB) with 
lower target doses. In contrast, they received more 
frequent mineralocorticoid receptor antagonists 
(MRA), but without differences in target doses of 
MRA between studied groups. Patients with non-
ischemic and non-hypertensive HF more often 
needed symptomatic treatment with loop diuretics 
and digoxin and had cardiac resynchronization ther-
apy (CRT) and implanted cardioverter-defibrillator 
(ICD) implanted in contrast to patients from other 
groups (Table 2).
Evaluation of patients’ past medical history 
revealed that in the group of patients with non-
ischemic and non-hypertensive etiology of HF 
Figure 3. The prevalence of non-ischemic and non-
-hypertensive etiology of heart failure according to age 
and gender of patients with stable systolic heart failure 
(n = 5563).
Figure 1. Distribution of etiology in studied group of 
patients with systolic heart failure.
Figure 2. Age and gender distribution of outpatients 
with stable systolic heart failure (n = 5563).
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there were more cardiac hospitalizations (both 
urgent and planned) than in hypertensive group, 
however there was no significant difference when 
compared with the ischemic group. There were 
differences in all non-cardiac hospitalizations and 
the total number of hospital admissions. Patients 
with non-ischemic and non-hypertensive HF were 
less often seen in outpatient clinics than other 
groups (Table 3).
Discussion
The major finding of this study revealed HF 
of non-ischemic and non-hypertensive origin 
Table 1. Baseline clinical characteristics, co-morbidities and signs of heart failure in three groups of  
patients: with non-ischemic and non-hypertensive etiology, with hypertensive and non-ischemic  
etiology, with ischemic etiology.
Parameters Patients with systolic HF (n = 5563) c2 P
Studied groups
Non-ischemic, 
non-hypertensive 
HF (n = 546; 10%) 
Hypertensive  
non-ischemic HF 
(n = 764; 14%)
Ischemic HF  
(n = 4253; 76%)
Baseline characteristics
Women 191 (36)aaa 371 (49)bbb 1441 (35) 61 < 0.0001
Age [years] 60 [50–69]aaa 67 [59–75]bbb 69 [61–76]ccc 126 < 0.0001
BMI [kg/m2] 27 [24–29]aaa 28 [26–31] 28 [26–30] 40 < 0.0001
Obesity: BMI > 30 kg/m2 106 (20%)aaa 243 (33%) 1217 (30%)ccc 26 < 0.0001
NYHA: III + IV 244 (47%)a 198 (41%) 1412 (34%)ccc 2 0.002
Heart rate ≥ 70 bpm 399 (74%)aa 610 (80%)bbb 2980 (71%) 30 < 0.001
SBP > 140 or DBP > 90 mm Hg 
on the outpatient’s office visit
101 (19%)aaa 359 (48%)bbb 1643 (39%)ccc 117 < 0.0001
HF diagnosis [years] 4 [2–7] 4 [2–7]bb 4 [2–9]cc 10 0.008
LVEF [%] 33 [25–40]aaa 40 [34–41] 38 [31–40] 64 < 0.0001
LVEF ≤ 35% 337 (62%)aaa 281 (37%) 1792 (42%)ccc 91 < 0.0001
Co-morbidities
Hypertension 0 (0%)aaa 764 (100%)bbb 3083 (72%)ccc 1587 < 0.0001
Previous stroke/TIA 65 (12%)aa 133 (17%) 797 (19%)ccc 16 < 0.001
Atrial fibrillation 243 (45%) 365 (48%)bbb 1303 (31%)ccc 112 < 0.0001
Cancer 14 (3%) 14 (2%) 108 (3%) 1 NS
COPD/asthma 63 (12%)aa 130 (17%)b 582 (14%) 9 0.01
Previous AMI 0aaa 0 3075 (72%)ccc 2117 < 0.0001
DM type 2 76 (14%)aaa 236 (31%)bb 1566 (37%)ccc 117 < 0.0001
Signs of heart failure
Lung congestion 76 (14%) 85 (11%)b 361 (8%)ccc 20 < 0.001
Peripheral oedema (20%) (22%)bb (17%) 10 0.008
Hepatomegaly 188 (34%)aaa 196 (26%) 1080 (25%)ccc 21 < 0.0001
Jugular vein distension 131 (24%)aa 138 (18%) 672 (16%)ccc 24 < 0.0001
Third heart sound 125 (23%)a 138 (18%) 712 (17%)ccc 13 0.002
AMI — acute myocardial infarction; BMI — body mass index; COPD — chronic obstructive pulmonary disease; DBP — diastolic blood pressure; 
DM — diabetes mellitus; HF — heart failure; LVEF — left ventricular ejection fraction; NS — non-significant; NYHA — New York Heart Asso-
ciation classification; SBP — systolic blood pressure; TIA — transient ischemic attack
Results are presented as a number of patients (and percentage) or median [with lower and upper quantil]. 
Legend: a/b/cp < 0.05; aa/bb/ccp < 0.01; aaa/bbb/cccp < 0.001, where: a — comparison between group 1 and 2; b — comparison between group 2 and 3; 
c — comparison between group 1 and 3. Lack of the letter “a/b/c” in some tables cells means that there is no significant difference between 
groups (p was non-significant for that comparison)
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predominantly affects young adults, who despite 
suffering from more advanced HF than patients 
with ischemic or hypertensive etiology of HF, are 
not optimally managed, possibly due to the lack 
of clinical trials and evidence based guidelines on 
how to treat patients with non-ischemic and non-
hypertensive HF.
Jankowska et al. [11] based on the same DATA-
-HELP registry has elegantly described some ob-
served differences between the clinical profile and 
management of outpatients with HF supervised by 
GPs versus those treated by cardiologists. They 
observed that patients treated by GPs were older, 
had more comorbidities, less commonly received 
beta-blocker and MRA, less often had implantable 
devices (ICD and CRT) and underwent coronary 
revascularization. Therefore, these findings should 
also be taken into consideration, as they may play 
a role in optimization and improvement in manage-
ment of outpatients with HF.
Ischemic heart disease (defined as a history 
of myocardial infarction, revascularization by PCI 
and/or CABG or coronary artery disease confirmed 
in coronarography), either alone (28%) or together 
Table 2. Comparison of treatment in systolic heart failure between three studied groups of patients: 
with non-ischemic and non-hypertensive etiology, with hypertensive and non-ischemic etiology, and 
with ischemic etiology.
Parameters Treatment of patients with systolic heart failure  
(n = 5563)
c2 P
Studied groups
Non-ischemic, 
non-hypertensive 
HF (n = 546; 10%)
Hypertensive, 
non-ischemic HF 
(n = 764; 14%)
Ischemic HF  
(n = 4253; 76%)
Revascularization
PCI 0 (0%)aaa 0 (0%)bbb 2205 (52%) 1125 < 0.0001
CABG 0 (0%)aaa 0 (0%)bbb 782 (18%) 280 < 0.0001
Implantable devices
ICD and/or CRT 91 (17%)aa 52 (7%) 359 (8%)cc 45 < 0.0001
CRT 47 (9%)aaa 22 (3%) 109 (3%)ccc 57 < 0.0001
Pacemaker 29 (5%) 40 (5%) 260 (6%) 1 NS
Medications
ACEI/ARB 518 (90%)aa 793 (94%) 4399 (95%)ccc 17 < 0.0001
ACEI/ARB — the target dose 65 (20%)aaa 168 (37%) 924 (36%)ccc 340 < 0.001
Beta-blocker 522 (96%) 726 (95%) b 4113 (97%) 6 0.04
Beta-blocker — the target dose 65 (13%) 94 (14%) 468 (12%) 2 NS
MRA 382 (70%)aaa 447 (59%) 2539 (60%)ccc 23 < 0.0001
MRA — the target dose 110 (21%) 141 (19%) 742 (18%) 2 NS
Statin 262 (48%)aaa 510 (67%)bbb 3791 (89%)ccc 696 < 0.0001
Calcium channel blocker 50 (9%)aaa 218 (29%) 1083 (26%)ccc 79 < 0.0001
Loop diuretic 379 (69%)a 487 (64%) 1617 (62%)ccc 13 0.001
Loop diuretics ≥ 100 mg/day 31 (6%) 36 (5%) 155 (4%)c 7 0.03
Thiazide diuretic 127 (23%)aaa 242 (32%)bbb 1042 (25%) 19 < 0.0001
Both diuretics 463 (85%) 667 (87%)bbb 3408 (80%)cc 26 < 0.0001
Digoxin 189 (35%)aaa 196 (26%)bbb 763 (18%)ccc 96 < 0.0001
Nitrates 37 (7%) 57 (8%)bbb 1130 (27%)ccc 220 < 0.0001
Antiplatelet drugs 248 (45%)aaa 437 (57%)bbb 3564 (84%)ccc 576 < 0.0001
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; CABG — coronary artery bypass grafting; CRT-D — 
cardiac resynchronization therapy defibrillator with pacing capabilities; HF — heart failure; ICD — implantable cardiac device; MRA — mine-
ralocorticoid receptor antagonist; NS — non-significant; PCI — percutaneous coronary intervention
Results are presented as a number of patients (and percentage) or median [with lower and upper quantil]. 
Legend: a/b/cp < 0.05; aa/bb/ccp < 0.01; aaa/bbb/cccp < 0.001, where: a — comparison between group 1 and 2; b — comparison between group 2 and 3; 
c — comparison between group 1 and 3. Lack of the letter “a/b/c” in some tables cells means that there is no significant difference between 
groups (p was non-significant for that comparison)
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with hypertension (72%), is the most common 
cause of HF and is present in three-fourths of 
outpatients with chronic HF. It is noteworthy here 
to mention the study from McMurray et al. [2], in 
which they raised difficulties with clear adjust-
ment of primary etiology of HF in patients with 
multiple potential causes (especially with coex-
isting ischemic heart disease and hypertension). 
Hypertension, without concomitant diagnosis of 
ischemic heart disease, was the second most com-
mon cause of HF. In comparison with the Rywik et 
al. study [12] noteing the prevalence of coexisting 
ischemic and hypertensive etiology of HF which 
has remained at a similar level in Poland for more 
than 10 years (55% in the present study vs. 53%), 
while ischemic heart disease alone appears less 
often to be a primary cause of HF than in the previ-
ous decade (21% vs. 26%). Nowadays hypertension 
as a primary cause of HF is more common (14% vs. 
8%), whereas non-ischemic and non-hypertensive 
etiology of HF has slightly decreased currently 
(10% vs. 12%) [12].
In the studied registry, non-ischemic and non-
hypertensive etiology of HF was found in every tenth 
outpatient with systolic HF and this prevalence in-
creased up to 46% in patients below 50 years of age.
Among patients with non-ischemic and non-
hypertensive HF there are patients suffering from 
cardiac arrhythmias, valve dysfunction, cardio-
myopathy (dilated, alcoholic, toxic, idiopathic etc.), 
pericardial disease (i.e. constrictive pericarditis) or 
past infections (viral myocarditis, rheumatic fever, 
HIV, Chagas disease) [2, 3, 13]. Unfortunately, the 
diagnostic process to discover etiology of HF often 
only results in eliminating some of the possible 
causes i.e. ischemic, hypertensive and arrhythmic 
and valve dysfunction. Thus, many patients are 
labelled as ‘non-ischemic and non-hypertensive’ 
HF, without finding the underlying cause of HF 
and as a consequence, it could be difficult, if not 
Table 3. Number of hospitalizations and outpatient visits within 12 preceding months in three groups 
of patients: with non-ischemic and non-hypertensive etiology, with hypertensive and non-ischemic 
etiology, with ischemic etiology.
Parameters Hospitalizations and outpatients’ visits  
within 1 preceding year
Patients with systolic HF (n = 5563)
c2 P
Studied groups
Non-ischemic, 
non-hypertensive 
HF (n = 546; 10%) 
Hypertensive, 
non-ischemic HF 
(n = 764; 14%)
Ischemic HF  
(n = 4253; 76%)
Hospitalizations
Urgent, in cardiac department 1.31 ± 1.15aa 1.10 ± 1.11bb 1.26 ± 1.12 15 0.0004
Planned, in cardiac department 1.09 ± 0.96aa 0.91 ± 0.95b 1.00 ± 1.00 10 0.007
All (urgent and planned),  
in cardiac department 
2.16 ± 1.71aa 1.75 ± 1.68bbb 2.14 ± 1.84 18 0.0001
Urgent, in other departments 0.93 ± 1.05 1.00 ± 1.03 1.04 ± 1.10 3 0.2
Planned, in other departments 0.70 ± 0.90a 0.86 ± 0.96 0.77 ± 0.93 6 0.04
All (urgent and planned),  
in other departments 
1.40 ± 1.53 1.51 ± 1.54 1.52 ± 1.67 1 0.6
All hospitalizations 3.34 ± 2.86 2.93 ± 2.65 3.26 ± 3.04 3 0.2
Outpatients visits
In internal medicine clinics 1.93 ± 1.63aaa 2.54 ± 1.58 2.50 ± 1.62ccc 37 < 0.0001
In cardiac clinics 2.90 ± 1.28aa 2.71 ± 1.29b 2.85 ± 1.33 7 0.03
In general practitioner’s  
practice 
2.96 ± 1.50 3.10 ± 1.55 3.20 ± 1.47cc 11 0.004
In other specialists’ clinics 1.20 ± 1.39aaa 1.78 ± 1.50 1.73 ± 1.53ccc 36 < 0.0001
All outpatinets’ visits 8.19 ± 3.77aaa 9.39 ± 4.12 9.58 ± 4.21ccc 28 < 0.0001
HF — heart failure; Results are presented as a mean number of hospitalizations/visits (with standard deviations). 
Legend: a/b/cp < 0.05; aa/bb/ccp < 0.01; aaa/bbb/cccp < 0.001, where: a — comparison between group 1 and 2; b — comparison between group 2  
and 3; c — comparison between group 1 and 3. Lack of the letter “a/b/c” in some of the table cells means that there is no significant difference 
between groups (p was non-significant for that comparison).
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impossible to treat them effectively. Taking into 
account possible causes of HF in the group of 
patients with non-ischemic and non-hypertensive 
HF in this study it was found that 45% of patients 
had a history of atrial fibrillation (more than in 
ischemic group — 31%, p < 0.0001, but similar to 
hypertensive group — 48%), 27% had valve dys-
function (more than in the ischemic group — 10%, 
p < 0.001, but less than in the hypertensive group 
— 33%, p < 0.05; however there is an important 
limitation in the interpretation of this data from 
the registry — there was no information about 
location and severity of valve dysfunction), 35% 
had possible post-infectious etiology (more than in 
ischemic — 1% and hypertensive group — 12%, 
all p < 0.001) and 10% were alcoholics (again 
more than in ischemic — 2.5% and hypertensive 
group — 3%, all p < 0.001). After exclusions of 
the aforementioned diagnosed and potential causes 
of HF in 108 patients (2% of all studied patients 
with HF and 20% of patients classified primary as 
non-ischemic and non-hypertensive etiology), no 
possible etiology has been found and can be clas-
sified as idiopathic HF. Especially in this popula-
tion of patients with HF, it appears to be justified 
to perform more sophisticated investigations like 
cardiac magnetic resonance or even heart biopsy, 
however it must be pointed out, that these kinds of 
examinations should take place only in clinics with 
experience in performing and describing results of 
these procedures [14–24].
It appeared that only suggestions about di-
agnosis were obtained, without clear guidelines 
how treat patients with non-ischemic and non-
hypertensive cause of HF.
The registry revealed that patients with non-
ischemic and non-hypertensive etiology were treat-
ed sub-optimally according to the latest ESC guide-
lines on treatment of HF with reduced LVEF [1]. 
Not only did fewer patients from this group 
receive ACEI/ARB (90%), but they also rarely 
achieved the target dose of those medications 
(only 20% of patients). Patients with non-ischemic 
and non-hypertensive HF were more frequently 
treated with MRA (70%). There was however, no 
difference in achieving the target dose of MRA 
between the studied groups. Despite a great im-
provement in treatment and outcomes in patients 
with HF over the last two decades [25], there are 
still many problems in reaching the target doses of 
recommended medications in ambulatory practice 
dispite this issue having been widely discussed 
in the literature [26, 27]. In the group of patients 
with non-ischemic and non-hypertensive etiology 
reported more hospitalizations in cardiac depart-
ments than in the hypertensive group and fewer 
outpatient visits. 
It was observed that despite substantial per-
centage of patients having indications for implanta-
tion of CRT/ICD device only 9% finally had such 
a device implanted. Of note, patients with non-
ischemic and non-hypertensive HF received ICD/ 
/CRT therapy twice as often than the two other 
group. Van Veldhuisen et al. [28] on the basis of the 
EUROMED Registry pointed out that implantable 
devices are underutilised in CHF patients with ma-
jor differences across various countries (with the 
highest rate of ICD implants in Germany and the 
lowest rate was in Spain; data from Poland was not 
obtained). In the ESC-HF Pilot Survey performed 
in 12 European countries during the same time 
frame as the present study — from October 2009 to 
May 2010 — only 23% of patients with chronic HF 
had ICD/CRT implanted [29]. Also, in the recent 
PARADIGM-HF trial, despite careful selection of 
optimally managed patients, again 22% received 
CRT/ICD therapy [30].
Limitation of the study 
An important limitation of this study, as in 
all registries performed on large populations 
in multicenter settings, is that it is linked with 
a questionnaire type study and has limited opportu-
nities for data verification. It must be emphasized, 
that this study relied entirely on the judgement of 
physicians regarding the underlying etiology of 
HF in their patients. Therefore, as in all studies 
based on questionnaires, assumptions were taken 
that all data would be provided reliably according 
to the rules of Good Clinical Practice, including the 
selection of patients to be recruited for the registry 
as well as the reporting of all data.
Despite the aforementioned limitations, there 
is also a great advantage of these type of studies. 
They reflect a real-world clinical practice which 
can be confronted with the applicable guidelines, 
thus answering an important question: how do 
physicians treat ten consecutive patients with HF 
for whom they are fully responsible?
During the study design 7900 outpatients 
were expected to be included in the registry (by 
500 cardiologists and 290 GPs), but completed data 
was obtained in just 5563 of those patients. Never-
theless, the big sample size allowed treating this 
population as representative of Polish outpatients 
with stable systolic heart failure.
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Conclusions
Currently in Poland every tenth patient with 
systolic HF has non-ischemic and non-hyperten-
sive underlying etiology of HF, with high preva-
lence in younger adults and in every second patient 
below 50 years old. Despite younger age and 
a low prevalence of comorbidities, patients with 
non-ischemic and non-hypertensive HF suffer 
from more advanced HF (defined as lower LVEF, 
NYHA class III or IV and signs of HF on physical 
examination) than patients with ischemic or hyper-
tensive etiology. Patients with non-ischemic and 
non-hypertensive HF remain not optimally man-
aged (according to the ESC guidelines for HF) and 
more commonly require symptomatic treatment.
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